Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

Nina D. Wagner-Johnston, Brian K. Link, Michelle Byrtek, Keith L. Dawson, John Hainsworth, Christopher R. Flowers, Jonathan W. Friedberg, Nancy L. Bartlett

Blood (2015) 126 (7): 851–857.

https://doi.org/10.1182/blood-2015-01-621375

Published: 2015

Journal Articles

Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

Christopher R Flowers, MD, MS, Michael Taylor, PharmD, PhD, Michelle Byrtek, PhD, Jamie H. Hirata, PharmD, James Cerhan, MD, PhD, John Hainsworth, MD, Brian Link, Thomas P. Miller, MD, Hildy Dillon, MPH, Jonathan W. Friedberg, MD

Blood (2010) 116 (21): 1768.

https://doi.org/10.1182/blood.V116.21.1768.1768

Published: 2010

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

Patterns of Care in Follicular Lymphoma (FL): Are Minorities Being Treated Differently? Report from the National LymphoCare Study (NLCS).

Chadi Nabhan, MD, FACP, Ewelina Morawa, MD, Jacob D. Bitran, MD, FACP, Michael D. Taylor, PhD, Ming Lin, Elaine K. Wong, MD, John Hainsworth, MD

Blood (2007) 110 (11): 367.

https://doi.org/10.1182/blood.V110.11.367.367

Published: 2007

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD

Blood (2006) 108 (11): 691.

https://doi.org/10.1182/blood.V108.11.691.691

Published: 2006

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.

Brian K. Link, James R. Cerhan, Hildy Dillon, Charles M. Farber, Susan Feliciano, Jonathan W. Friedberg, John Hainsworth, Ron Steis, Julie M. Vose, Andrew D. Zelenetz

Blood (2005) 106 (11): 1000.

https://doi.org/10.1182/blood.V106.11.1000.1000

Published: 2005

Journal Articles

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, John F. Bender, PharmD

Blood (2004) 104 (11): 587.

https://doi.org/10.1182/blood.V104.11.587.587

Published: 2004

Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD

Blood (2004) 104 (11): 2480.

https://doi.org/10.1182/blood.V104.11.2480.2480

Published: 2004

Journal Articles

Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Aggressive Non-Hodgkin’s Lymphoma (NHL); Initial Results of Induction Therapy, Including Rituximab Pharmacokinetics, in a Phase II Study.

Jane E. Huang, MD, Alfred Saleh, MD, J. Thomas Lee, MD, Virginia Langmuir, MD, Fan Zhang, John Hainsworth, MD

Blood (2004) 104 (11): 4616.

https://doi.org/10.1182/blood.V104.11.4616.4616

Published: 2004

NARROW

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Patterns of Care in Follicular Lymphoma (FL): Are Minorities Being Treated Differently? Report from the National LymphoCare Study (NLCS).

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Aggressive Non-Hodgkin’s Lymphoma (NHL); Initial Results of Induction Therapy, Including Rituximab Pharmacokinetics, in a Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only